Tag - SLDB

Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024

Markets

Spheric BioCantor starts Solid at OW; PT $5

Cantor Fitzgerald launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “overweight” rating and 12-month price target of $5. The stock closed at $2.76 on Sept. 22. Solid is using its gene therapy platform to...

September 25, 2023

Markets

SVB Leerink ups Solid Biosciences to OP from MP; PT to $15 from $3

SVB Leerink upgraded Solid Biosciences (NASDAQ:SLDB) to “outperform” from “market perform” and raised its price target to $15 from $3, citing the first functional data for the company’s microdystrophin gene...

March 16, 2021

Tag - SLDB

William Blair starts Solid Biosciences at OP

Spheric BioCantor starts Solid at OW; PT $5

SVB Leerink ups Solid Biosciences to OP from MP; PT to $15 from $3

General

More